PriceTargets.com logo

Alto Neuroscience - ANRO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $37.25
  • Forecasted Upside: 23.94%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$30.05 As of 09/16/2026 04:59 PM ET
▼ -0.196 (-0.65%)

This chart shows the closing price for ANRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alto Neuroscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANRO

Analyst Price Target is $37.25
▲ +23.94% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Alto Neuroscience in the last 3 months. The average price target is $37.25, with a high forecast of $55.00 and a low forecast of $26.00. The average price target represents a 23.94% upside from the last price of $30.05.

This chart shows the closing price for ANRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in Alto Neuroscience. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/18/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
8/17/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/16/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/20/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
8/17/2026HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $55.00
8/13/2026WedbushBoost TargetNeutral ➝ Neutral$24.00 ➝ $26.00
8/13/2026BTIG ResearchBoost TargetBuy ➝ Buy$28.00 ➝ $37.00
7/29/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/22/2026Zacks ResearchDowngradeHold ➝ Strong Sell
6/17/2026HC WainwrightReiterated RatingBuy ➝ Buy
5/27/2026HC WainwrightReiterated RatingBuy ➝ Buy$50.00
5/22/2026Wolfe ResearchInitiated CoverageOutperform
5/18/2026Robert W. BairdLower TargetOutperform ➝ Outperform$38.00 ➝ $36.00
5/14/2026WedbushBoost TargetNeutral ➝ Neutral$21.00 ➝ $24.00
5/11/2026HC WainwrightReiterated RatingBuy ➝ Buy$50.00
5/5/2026Bank of AmericaInitiated CoverageBuy$35.00
5/1/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
4/22/2026Chardan CapitalReiterated RatingBuy ➝ Buy$30.00
4/2/2026Robert W. BairdLower TargetOutperform ➝ Outperform$41.00 ➝ $38.00
4/2/2026HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/2/2026JonesTradingLower TargetBuy ➝ Buy$49.00 ➝ $44.00
4/2/2026WedbushLower TargetNeutral ➝ Neutral$22.00 ➝ $21.00
4/2/2026Chardan CapitalReiterated RatingBuy ➝ Buy$30.00
3/18/2026Robert W. BairdBoost TargetOutperform ➝ Outperform$22.00 ➝ $41.00
3/17/2026WedbushBoost TargetNeutral ➝ Neutral$13.00 ➝ $22.00
3/17/2026Chardan CapitalReiterated RatingBuy ➝ Buy$30.00
3/16/2026Jefferies Financial GroupReiterated RatingBuy ➝ Buy$35.00
2/17/2026BTIG ResearchBoost TargetBuy ➝ Buy$27.00 ➝ $28.00
1/5/2026Chardan CapitalBoost TargetBuy ➝ Buy$15.00 ➝ $30.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/19/2025Chardan CapitalUpgradeStrong-Buy
11/17/2025BTIG ResearchInitiated CoverageBuy$27.00
11/13/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$16.00 ➝ $22.00
11/12/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$15.00 ➝ $25.00
10/24/2025HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $50.00
10/20/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$10.00 ➝ $16.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/29/2025Chardan CapitalInitiated CoverageBuy$15.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00
6/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00
5/15/2025WedbushReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
4/7/2025HC WainwrightInitiated CoverageBuy$10.00
3/21/2025William BlairReiterated RatingOutperform
11/13/2024Stifel NicolausLower TargetBuy ➝ Buy$32.00 ➝ $10.00
10/23/2024WedbushDowngradeOutperform ➝ Neutral$29.00 ➝ $4.00
10/23/2024Robert W. BairdLower TargetOutperform ➝ Outperform$32.00 ➝ $10.00
10/23/2024Rodman & RenshawDowngradeBuy ➝ Neutral
9/10/2024William BlairReiterated RatingOutperform
9/10/2024WedbushReiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00
9/3/2024WedbushInitiated CoverageOutperform$29.00
6/21/2024Rodman & RenshawInitiated CoverageBuy$43.00
6/12/2024William BlairReiterated RatingOutperform
5/15/2024William BlairReiterated RatingOutperform
3/25/2024Stifel NicolausReiterated RatingBuy ➝ Buy$32.00
2/27/2024William BlairInitiated CoverageOutperform
2/27/2024TD CowenInitiated CoverageOutperform
2/27/2024Robert W. BairdInitiated CoverageOutperform$32.00
2/27/2024Jefferies Financial GroupInitiated CoverageBuy$33.00
2/27/2024Stifel NicolausInitiated CoverageBuy$32.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/19/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/17/2026
  • 8 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 8 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Alto Neuroscience logo
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Read More

Today's Range

Now: $30.05
Low: $29.87
High: $31.21

50 Day Range

MA: $30.96
Low: $26.00
High: $36.75

52 Week Range

Now: $30.05
Low: $3.59
High: $37.48

Volume

548,376 shs

Average Volume

385,189 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Alto Neuroscience?

The following Wall Street sell-side analysts have issued reports on Alto Neuroscience in the last twelve months: Bank of America Corporation, BTIG Research, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., JonesTrading, Robert W. Baird, Wall Street Zen, Wedbush, Weiss Ratings, Wolfe Research, and Zacks Research.
View the latest analyst ratings for ANRO.

What is the current price target for Alto Neuroscience?

0 Wall Street analysts have set twelve-month price targets for Alto Neuroscience in the last year. Their average twelve-month price target is $37.25, suggesting a possible upside of 22.4%. HC Wainwright has the highest price target set, predicting ANRO will reach $55.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $26.00 for Alto Neuroscience in the next year.
View the latest price targets for ANRO.

What is the current consensus analyst rating for Alto Neuroscience?

Alto Neuroscience currently has 1 sell rating, 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ANRO.

What other companies compete with Alto Neuroscience?

Other companies that are similar to Alto Neuroscience include Veradermics, Indivior, Organon & Co., Tarsus Pharmaceuticals and Arcutis Biotherapeutics. Learn More about companies similar to Alto Neuroscience.

How do I contact Alto Neuroscience's investor relations team?

Alto Neuroscience's physical mailing address is 650 Castro Street, Suite 450, Mountain View, CA, 94041. The company's listed phone number is (773) 255-5012 and its investor relations email address is [email protected]. The official website for Alto Neuroscience is www.altoneuroscience.com. Learn More about contacing Alto Neuroscience investor relations.